HDAC6 detector: online application for evaluating compounds as potential histone deacetylase 6 inhibitors

References

• T.C.S. Ho, A.H.Y. Chan, and A. Ganesan, Thirty years of HDAC inhibitors: 2020 insight and hindsight, J. Med. Chem. 63 (2020), pp. 12460–12484. doi:10.1021/acs.jmedchem.0c00830.
   PubMed Web of Science ®Google Scholar
• X.X. Wang, R.Z. Wan, and Z.P. Liu, Recent advances in the discovery of potent and selective HDAC6 inhibitors, Eur. J. Med. Chem. 143 (2018), pp. 1406–1418. doi:10.1016/j.ejmech.2017.10.040.
   PubMed Web of Science ®Google Scholar
• Z. Rana, S. Diermeier, M. Hanif, and R.J. Rosengren, Understanding failure and improving treatment using HDAC inhibitors for prostate cancer, Biomedicines 8 (2020), pp. 22.
   PubMed Web of Science ®Google Scholar
• T. Li, C. Zhang, S. Hassan, X. Liu, F. Song, K. Chen, W. Zhang, and J. Yang, Histone deacetylase 6 in cancer, J. Hematol. Oncol. 11 (2018), pp. 111.
   PubMed Web of Science ®Google Scholar
• G.I. Aldana-Masangkay and K.M. Sakamoto, The role of HDAC6 in cancer, J. Biomed. Biotechnol. 2011 (2011), pp. 875824. doi:10.1155/2011/875824.
   PubMed Web of Science ®Google Scholar
• B.T. Scroggins, K. Robzyk, D. Wang, M.G. Marcu, S. Tsutsumi, K. Beebe, R.J. Cotter, S. Felts, D. Toft, L. Karnitz, N. Rosen, and L. Neckers, An acetylation site in the middle domain of Hsp90 regulates chaperone function, Mol. Cell. 25 (2007), pp. 151–159. doi:10.1016/j.molcel.2006.12.008.
   PubMed Web of Science ®Google Scholar
• J. Trepel, M. Mollapour, G. Giaccone, and L. Neckers, Targeting the dynamic HSP90 complex in cancer, Nat. Rev. Cancer 10 (2010), pp. 537–549.
   PubMed Web of Science ®Google Scholar
• L. Whitesell and S.L. Lindquist, HSP90 and the chaperoning of cancer, Nat. Rev. Cancer 5 (2005), pp. 761–772.
   PubMed Web of Science ®Google Scholar
• B. Zhou, D. Liu, and Y. Tan, Role of HDAC6 and its selective inhibitors in gastrointestinal cancer, Front. Cell Dev. Biol. 9 (2021), pp. 719390. doi:10.3389/fcell.2021.719390.
   PubMed Web of Science ®Google Scholar
• T. Onishi, R. Maeda, M. Terada, S. Sato, T. Fujii, M. Ito, K. Hashikami, T. Kawamoto, and M. Tanaka, A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer’s disease and tauopathy in mice, Sci. Rep. 29 (2021), pp. 15423. doi:10.1038/s41598-021-94923-w.
   Google Scholar
• D. Bae, J.Y. Lee, N. Ha, J. Park, J. Baek, D. Suh, H.S. Lim, S.M. Ko, T. Kim, D. Som Jeong, and W.C. Son, CKD-506: A novel HDAC6-selective inhibitor that exerts therapeutic effects in a rodent model of multiple sclerosis, Sci. Rep. 11 (2021), pp. 14466. doi:10.1038/s41598-021-93232-6.
   PubMed Web of Science ®Google Scholar
• S.V. Demyanenko, V.A. Dzreyan, and A.B. Uzdensky, Overexpression of HDAC6, but not HDAC3 and HDAC4 in the penumbra after photothrombotic stroke in the rat cerebral cortex and the neuroprotective effects of α-phenyl tropolone, HPOB, and sodium valproate, Brain Res. Bull. 162 (2020), pp. 151–165. doi:10.1016/j.brainresbull.2020.06.010.
   PubMed Web of Science ®Google Scholar
• M.V. Kozlov, A.A. Kleymenova, L.I. Romanova, K.A. Konduktorov, K.A. Kamarova, O.A. Smirnova, V.S. Prassolov, and S.N. Kochetkov, Pyridine hydroxamic acids are specific anti-HCV agents affecting HDAC6, Bioorg. Med. Chem. Lett. 25 (2015), pp. 2382–2385. doi:10.1016/j.bmcl.2015.04.016.
   PubMed Web of Science ®Google Scholar
• I. Çakır, C.K. Hadley, P.L. Pan, R.A. Bagchi, M. Ghamari-Langroudi, D.T. Porter, Q. Wang, M.J. Litt, S. Jana, S. Hagen, P. Lee, A. White, J.D. Lin, T.A. McKinsey, and R.D. Cone, Histone deacetylase 6 inhibition restores leptin sensitivity and reduces obesity, Nat. Metab. 4 (2022), pp. 44–59.
   PubMedGoogle Scholar
• J. Li, M. Yu, S. Fu, D. Liu, and Y. Tan, Role of selective histone deacetylase 6 inhibitor ACY-1215 in cancer and other human diseases, Front. Pharmacol. 13 (2022), pp. 1117936. doi:10.3389/fphar.2022.1117936.
   PubMed Web of Science ®Google Scholar
• V.N. Osipov, D.S. Khachatryan, and A.N. Balaev, Biologically active quinazoline-based hydroxamic acids, Med. Chem. Res. 29 (2020), pp. 831–845. doi:10.1007/s00044-020-02530-7.
   Web of Science ®Google Scholar
• E.N. Muratov, J. Bajorath, R.P. Sheridan, I.V. Tetko, D. Filimonov, V. Poroikov, T.I. Oprea, I.I. Baskin, A. Varnek, A. Roitberg, O. Isayev, S. Curtalolo, D. Fourches, Y. Cohen, A. Aspuru-Guzik, D.A. Winkler, D. Agrafiotis, A. Cherkasov, and A. Tropsha, QSAR without borders, Chem. Soc. Rev 49 (2020), pp. 3525–3716.
   PubMed Web of Science ®Google Scholar
• O.V. Tinkov, V.Y. Grigorev, L.D. Grigoreva, V.N. Osipov, A.V. Kolotaev, and D.S. Khachatryan, QSAR analysis and experimental evaluation of new quinazoline-containing hydroxamic acids as histone deacetylase 6 inhibitors, SAR QSAR Environ. Res. 33 (2022), pp. 513–532. doi:10.1080/1062936X.2022.2092210.
   PubMed Web of Science ®Google Scholar
• O.V. Tinkov, V.Y. Grigorev, and L.D. Grigoreva, QSAR Analysis of HDAC6 Inhibitors, Moscow Univ. Chem. Bull. 77 (2022), pp. S25–S35. doi:10.3103/S0027131422070100.
   Google Scholar
• D. Ruzic, N. Djokovic, and K. Nikolic, Fragment-based drug design of selective HDAC6 inhibitors, Meth. Mol. Biol. 2266 (2021), pp. 155–170.
   PubMedGoogle Scholar
• D. Ruzic, M. Petkovic, D. Agbaba, A. Ganesan, and K. Nikolic, Combined ligand and fragment-based drug design of selective histone deacetylase - 6 inhibitors, Mol. Inform. 38 (2019), pp. e1800083. doi:10.1002/minf.201800083.
   PubMed Web of Science ®Google Scholar
• C. Hu, L. Hong, and W. Du, 3D-QSAR studies of HDAC6 Inhibitors using docking-based alignment, Lett. Drug Des. Discov. 14 (2017), pp. 798–810. doi:10.2174/1570180813666161028165151.
   Web of Science ®Google Scholar
• S. Vijayasarathy and J. Chatterjee, Comparative QSAR analysis of histone deacetylase 6 (hdac6) inhibitors as anti-cancer agents, Int. J. Curr. Res. 8 (2016), pp. 39618–39623.
   Google Scholar
• C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Deliv. Rev. 46 (2001), pp. 3–26. doi:10.1016/S0169-409X(00)00129-0.
   PubMed Web of Science ®Google Scholar
• D. Mendez, A. Gaulton, A.P. Bento, J. Chambers, M. De Veij, E. Félix, M.P. Magariños, J.F. Mosquera, P. Mutowo, M. Nowotka, M. Gordillo-Marañón, F. Hunter, L. Junco, G. Mugumbate, M. Rodriguez-Lopez, F. Atkinson, N. Bosc, C.J. Radoux, A. Segura-Cabrera, A. Hersey, and A.R. Leach, ChEMBL: Towards direct deposition of bioassay data, Nucl. Acids Res. 47 (2019), pp. D930–D940. doi:10.1093/nar/gky1075.
   PubMed Web of Science ®Google Scholar
• M. Swain, MolVS: molecule validation and standardization tool, 2019; software available at https://molvs.readthedocs.io/en/latest/guide/intro.html
   Google Scholar
• G. Landrum, RDKit - open source toolkit for cheminformatics, 2013; software available at https://www.rdkit.org/docs/index.html
   Google Scholar
• F. Pedregosa, G. Varoquaux, A. Gramfort, V. Michel, B. Thirion, O. Grisel, M. Blondel, P. Prettenhofer, R. Weiss, V. Dubourg, J. Vanderplas, A. Passos, D. Cournapeau, M. Brucher, M. Perrot, and E. Duchesnay, Scikit-learn: Machine learning in Python, JMLR. 12 (2011), pp. 2825–2830.
   Web of Science ®Google Scholar
• S. Jasial, Y. Hu, M. Vogt, and J. Bajorath, Activity-relevant similarity values for fingerprints and implications for similarity searching, F1000Res (2016), pp. 591. doi:10.12688/f1000research.8357.1.
   Google Scholar
• D. Krstajic, L.J. Buturovic, D.E. Leahy, and S. Thomas, Cross-validation pitfalls when selecting and assessing regression and classification models, J. Cheminform. 6 (2014), pp. 10. doi:10.1186/1758-2946-6-10.
   PubMed Web of Science ®Google Scholar
• V.M. Alves, S.J. Capuzzi, R.C. Braga, D. Korn, J.E. Hochuli, K.H. Bowler, A. Yasgar, G. Rai, A. Simeonov, E.N. Muratov, A.V. Zakharov, and A. Tropsha, SCAM detective: Accurate predictor of small, colloidally aggregating molecules, J. Chem. Inf. Model. 60 (2020), pp. 4056–4063. doi:10.1021/acs.jcim.0c00415.
   PubMed Web of Science ®Google Scholar
• Streamlit 1.10.0. is an open-source Python library; software available at https://docs.streamlit.io/
   Google Scholar
• G. Van Rossum and F.L. Drake, Python 3 Reference Manual, CreateSpace, Scotts Valley, CA, 2009.
   Google Scholar
• C.R. Harris, K.J. Millman, S.J. van der Walt, R. Gommers, P. Virtanen, D. Cournapeau, E. Wieser, J. Taylor, S. Berg, N.J. Smith, R. Kern, M. Picus, S. Hoyer, M.H. van Kerkwijk, M. Brett, A. Haldane, J. Fernandez Del Rio, M. Wiebe, P. Peterson, P. Gerard-Marchant, K. Sheppard, T. Reddy, W. Weckesser, H. Abbasi, C. Gohlke, and T.E. Oliphant, Array programming with NumPy, Nature 585 (2020), pp. 357–362. doi:10.1038/s41586-020-2649-2.
   PubMed Web of Science ®Google Scholar
• W. McKinney, Data structures for statistical computing in Python, 9th Python in Science Conference, Austin, 2010.
   Google Scholar
• J.D. Hunter, Matplotlib: A 2D graphics environment, Comput. Sci. Eng. 9 (2007), pp. 90–95. doi:10.1109/MCSE.2007.55.
   Web of Science ®Google Scholar
• Click 8.1.3. Python composable command line interface toolkit; software available at https://github.com/pallets/click
   Google Scholar
• Joblib: Running Python functions as pipeline jobs; software available at https://joblib.readthedocs.io/en/latest/
   Google Scholar
• S. Riniker and G.A. Landrum, Similarity maps - a visualization strategy for molecular fingerprints and machine-learning methods, J. Cheminform. 5 (2013), article number: 43. doi:10.1186/1758-2946-5-43.
   Web of Science ®Google Scholar
• J. Chen, J. Zhang, N.F. Shaik, B. Yi, X. Wei, X.F. Yang, U.P. Naik, R. Summer, G. Yan, X. Xu, and J. Sun, The histone deacetylase inhibitor tubacin mitigates endothelial dysfunction by up-regulating the expression of endothelial nitric oxide synthase, J. Biol. Chem. 294 (2019), pp. 19565–19576. doi:10.1074/jbc.RA119.011317.
   PubMed Web of Science ®Google Scholar
• L. Santo, T. Hideshima, A.L. Kung, J.C. Tseng, D. Tamang, M. Yang, M. Jarpe, J.H. van Duzer, R. Mazitschek, W.C. Ogier, D. Cirstea, S. Rodig, H. Eda, T. Scullen, M. Canavese, J. Bradner, K.C. Anderson, S.S. Jones, and N. Raje, Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma, Blood 119 (2012), pp. 2579–2589. doi:10.1182/blood-2011-10-387365.
   PubMed Web of Science ®Google Scholar
• T.E. Wood, S. Dalili, C.D. Simpson, M.A. Sukhai, R. Hurren, K. Anyiwe, X. Mao, F. Suarez Saiz, M. Gronda, Y. Eberhard, N. MacLean, T. Ketela, J.C. Reed, J. Moffat, M.D. Minden, R.A. Batey, and A.D. Schimmer, Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands, Mol. Cancer Ther. 9 (2010), pp. 246–256. doi:10.1158/1535-7163.MCT-09-0495.
   PubMed Web of Science ®Google Scholar
• Z. Yang, T. Wang, F. Wang, T. Niu, Z. Liu, X. Chen, C. Long, M. Tang, D. Cao, X. Wang, W. Xiang, Y. Yi, L. Ma, J. You, and L. Chen, Discovery of selective histone deacetylase 6 inhibitors using the quinazoline as the cap for the treatment of cancer, J. Med. Chem. 59 (2016), pp. 1455–1470. doi:10.1021/acs.jmedchem.5b01342.
   PubMed Web of Science ®Google Scholar
• D.S. Khachatryan, A.N. Balaev, K.A. Okhmanovich, A.V. Kolotaev, K.R. Matevosyan, and V.N. Osipov, Method of obtaining hydroxamic acids, derivatives of 2-aryl-2.3-dihydroquinazolin-4(1h)-ones, Patent RU2744750C1, Institute of Chemical Reagents and High Purity Chemical Substances of the National Research Centre “Kurchatov Institute”, Moscow, Russia, 2020. Available at https://patents.google.com/patent/RU2744750C1/en.
   Google Scholar
• V.N. Osipov, A.N. Balaev, A.V. Gromyko, A.V. Kolotaev, and D.S. Khachatryan, 3-hydroxyquinazoline-4(3h)-one derivatives as histone deacetylase inhibitors and a method for production thereof, Patent RU2740503C1, Institute of Chemical Reagents and High Purity Chemical Substances of the National Research Centre “Kurchatov Institute”, Moscow, Russia, 2020. Available at https://patents.google.com/patent/RU2740503C1/en
   Google Scholar
• L. Eriksson, J. Jaworska, A.P. Worth, M.T. Cronin, R.M. McDowell, and P. Gramatica, Methods for reliability and uncertainty assessment and for applicability evaluations of classification- and regression-based QSARs, Environ. Health Perspect. 111 (2003), pp. 1361–1375. doi:10.1289/ehp.5758.
   PubMed Web of Science ®Google Scholar
• J.H. Fentem, G.E. Archer, M. Balls, P.A. Botham, R.D. Curren, L.K. Earl, D.J. Esdaile, H.G. Holzhütter, and M. Liebsch, The ECVAM international validation study on in vitro tests for skin corrosivity. 2. results and evaluation by the management team, Toxicol. In Vitro 12 (1998), pp. 483–524. doi:10.1016/S0887-2333(98)00019-8.
   PubMed Web of Science ®Google Scholar
• A.A. Toropov, A.P. Toropova, G. Raitano, and E. Benfenati, CORAL: Building up QSAR models for the chromosome aberration test, Saudi J. Biol. Sci. 26 (2019), pp. 1101–1106. doi:10.1016/j.sjbs.2018.05.013.
   PubMed Web of Science ®Google Scholar
• V.M. Alves, T. Bobrowski, C.C. Melo‐Filho, D. Korn, S. Auerbach, C. Schmitt, E.N. Muratov, and A. Tropsha, QSAR modeling of SARS‐CoV M pro inhibitors identifies sufugolix, cenicriviroc, proglumetacin, and other drugs as candidates for repurposing against SARS‐CoV‐2, Mol. Inform. 40 (2021), pp. 2000113. doi:10.1002/minf.202000113.
   PubMed Web of Science ®Google Scholar
• A.S. Madsen and C.A. Olsen, A potent trifluoromethyl ketone histone deacetylase inhibitor exhibits class-dependent mechanism of action, Med. Chem. Commun. 7 (2016), pp. 464–470. doi:10.1039/C5MD00451A.
   Google Scholar
• L.M. Butler, Y. Webb, D.B. Agus, B. Higgins, T.R. Tolentino, M.C. Kutko, M.P. LaQuaglia, M. Drobnjak, C. Cordon-Cardo, H.I. Scher, R. Breslow, V.M. Richon, R.A. Rifkind, and P.A. Marks, Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase, Clin. Cancer Res. 7 (2001), pp. 962–970.
   PubMed Web of Science ®Google Scholar
• T. Ehrig, K.M. Bohren, F.G. Prendergast, and K.H. Gabbay, Mechanism of aldose reductase inhibition: Binding of NADP+/NADPH and alrestatin-like inhibitors, Biochemistry 33 (1994), pp. 7157–7165. doi:10.1021/bi00189a019.
   PubMed Web of Science ®Google Scholar
• F.W. Peng, J. Xuan, T.T. Wu, J.Y. Xue, Z.W. Ren, D.K. Liu, X.Q. Wang, X.H. Chen, J.W. Zhang, Y.G. Xu, and L. Shi, Design, synthesis and biological evaluation of N–phenylquinazolin–4–amine hybrids as dual inhibitors of VEGFR–2 and HDAC, Eur. J. Med. Chem. 109 (2016), pp. 1–12. doi:10.1016/j.ejmech.2015.12.033.
   PubMed Web of Science ®Google Scholar
• F.W. Peng, T.T. Wu, Z.W. Ren, J.Y. Xue, and L. Shi, Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase, Bioorg. Med. Chem. Lett. 25 (2015), pp. 5137–5141. doi:10.1016/j.bmcl.2015.10.006.
   PubMed Web of Science ®Google Scholar
• C. Ding, S. Chen, C. Zhang, G. Hu, W. Zhang, L. Li, Y.Z. Chen, C. Tan, and Y. Jiang, Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy, Bioorg. Med. Chem. 25 (2017), pp. 27–37. doi:10.1016/j.bmc.2016.10.006.
   PubMed Web of Science ®Google Scholar
• A. Frühauf and F.J. Meyer-Almes, Non-hydroxamate zinc-binding groups as warheads for histone deacetylases, Molecules 26 (2021), pp. 5151. doi:10.3390/molecules26175151.
   PubMed Web of Science ®Google Scholar